Abbott’s Lake County Plant Gets FDA Nod; Prism Squares Up For U.S. Debut

Abbott Labs will begin U.S. commercialization of its Prism, Architect and AxSYM full diagnostic assay menus over the next 12 months, following FDA's decision to end a four-year prohibition of product sales